Upper GI 2017

Neoscope Study – Cross Trial Comparison

OE05 (n= 897)

CROSS (n=368)

NEOSCOPE (n=85)

CF

ECX

CarPacRT

CarPacRT

OxCapRT

Grade 3/4 toxicity (any)

30%

47%

Haem 7% Other 13%

52.4%

42.1%

Surgical complications Resp:27% Cardiac: 11% Chylothx:3% Anas Leak:11%

Resp: 34% Cardiac: 12% Chylothx:4% Anas Leak:10%

Resp: 46% Cardiac: 21% Chylothx:10% Anas Leak:22%

Resp: 36.6% Cardiac: 9.8% Chylothx:4.9% Anas Leak:7.3%

Resp: 38.9% Cardiac: 25% Chylothx:2.8% Anas Leak:0%

Post op Mortality

30 day:2% 90 day:4%

30 day:2% 90 day:5%

30 day:4% (4% in S) >30 day:2% (3% in S)

30 day: 2.4% 90 day:

30 day: 2.8% 90 day:

TRG 1

3%

11%

29% (ACA23%; SC:49%)

27.9%

11.9%

2

3%

6%

32%

37.2%

31%

R0

60%

67% (p=0.059)

92% (69% in S)

80.5%

72.2%

Mukherjee S et al. ASCO-GI 2016

© Universitätsmedizin Leipzig: University Cancer Center Leipzig (UCCL), Prof. Dr. F. Lordick